PennyPusher786
10 months ago
Pretty much. You do the opposite of what they they want and you eventually catch a nice return or for some, a flip... I haven't been one to flip trade. Don't believe in it, but I guess I would be better off if I did...
When they say get vaccinated, it really means, don't... when they say EVs are the future, invest in oil.... when they say someone is a terrorist, they themselves are the terrorists...
You can apply that to every government and institutional narrative lol
PennyPusher786
10 months ago
https://aravive.com/pipeline/
Pipeline
Batiraxcept (formerly AVB-500), is an ultra-high affinity decoy protein that binds to GAS6 and thereby prevents AXL signaling to inhibit metastasis and tumor growth and restore sensitivity to anti-cancer agents. Batiraxcept is currently being evaluated in multiple clinical trials.
Batiraxcept has been granted Fast Track Designation by the U.S. FDA for both clear cell renal cell carcinoma and platinum-resistant ovarian cancer and Orphan Drug Designation for pancreatic ductal adenocarcinoma. Batiraxcept has been granted Orphan Drug Designation by the European Commission for platinum resistant recurrent ovarian cancer.
Analysis of all safety data to date showed that batiraxcept has been generally well tolerated with no dose-limiting toxicities or unexpected safety signals. A P1B platinum-resistant ovarian cancer trial (N = 53) demonstrated more than a doubling of progression-free survival in a patient subgroup that represents the P3 population.
?
?
Platinum Resistant Ovarian Cancer
Ovarian cancer ranks fifth in cancer deaths among women, and it is estimated by the American Cancer Society that there will be approximately 19,710 new cases of ovarian cancer in the United States and approximately 13,270 ovarian cancer deaths in the United States during 2023. Due to the nonspecific nature of disease symptoms and lack of validated screening tools in the general population, most women present with advanced disease. Although aggressive cytoreductive surgery and platinum- and taxane-based combination chemotherapy can place most patients into remission, disease recurrence manifests in greater than 70% of patients. Ultimately, patients who relapse become platinum-resistant and the identification of effective and tolerable treatment options is considered a high unmet clinical need. We are focused on addressing the high unmet need in this patient population and successfully completed a Phase 1b trial of batiraxcept in patients with platinum resistant ovarian cancer. We have completed enrollment in a registrational Phase 3 trial of batiraxcept in platinum resistant ovarian cancer (NCT04729608).
Clear Cell Renal Cell Carcinoma
Kidney cancer is a leading cause of cancer-related deaths in the United States and is among the 10 most common cancers in both men and women. According to the American Cancer Society, it is estimated that there will be approximately 81,800 new cases of kidney cancer and 14,890 people will die from this disease in the United States during 2023. Clear cell renal cell carcinoma is a cancer of the kidney and accounts for more than 75% of malignant kidney tumors. Metastasis to distant organs including the lung, bone, liver, and brain is the primary cause of death in kidney cancer patients, and only 12% of people with metastatic kidney cancer will survive past 5 years. We have completed enrollment in a Phase 1b/2 clinical trial of batiraxcept in patients with clear cell renal cell carcinoma (NCT04300140).
Pancreatic Adenocarcinoma
Pancreatic cancer is the seventh leading cause of cancer death worldwide. There were approximately 495,800 new cases of pancreatic cancer and 466,000 deaths from the disease worldwide in 2020. The American Cancer Society estimates 64,050 people will be diagnosed with pancreatic cancer and 50,550 people will die of pancreatic cancer in 2023. Pancreatic cancer typically has a poor prognosis, and the five-year survival rate is approximately 11%. Pancreatic adenocarcinoma is the most common type of pancreatic cancer, and there is a clear, high, unmet medical need to improve patient survival with new effective treatments that are safe and well-tolerated. Pancreatic cancer is projected to become the third leading cause of cancer death worldwide by 2025 and the second leading cause of cancer death in the U.S. by 2030. We have initiated and are recruiting for a Phase 1b/2 clinical trial of batiraxcept in patients with pancreatic adenocarcinoma (NCT04983407).
PennyPusher786
10 months ago
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Aravive (ARAV - Research Report) today and set a price target of $7.00. The company's shares opened today at $1.40.According to TipRanks, Pantginis is an analyst with an average return of -19.7% and a 26.95% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Decibel Therapeutics, and Biomea Fusion.Aravive has an analyst consensus of Strong Buy, with a price target consensus of $9.67, which is a 590.71% upside from current levels. In a report released on October 27, Roth Capital also maintained a Buy rating on the stock with a $10.00 price target.
https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-their-buy-rating-for-aravive-arav-2?utm_source=advfn.com&utm_medium=
PennyPusher786
10 months ago
Loading loading loading, to break higher lows and set new highs... .20s soon, 30s not far off and news sets this at $1+ currently presenting until Tuesday in Europe. They will get Approval of their drugs for treatment of cancer... This is a short killer, they go long as well as short playing both sides... But they have the funds to sit this out for months... a don't lose your shares. Add, add, add, if you're in losses, average down
PennyPusher786
10 months ago
Yeah, it's no secret... they pump it up and sell off by end of day. Same repetition on every ticker these days. Volume must sustain week after week and news updates have to come to justify and maintain momentum... a otherwise, you stay sub dollar, reverse split and stay sub dollar once more. Quantitative Easing ended and money supply tightened up... The money supply is now reserved for government agendas like the war in Ukraine and Israel, LGBTQ, Transgender & Gender b.s.... "Climate change," electric vehicles etc lol...
Either you fold or take losses or by some luck you got into the right ticker which rises week over week like HUBC TTOO, TPST GNS in january GTII in february, FNGR in recent weeks etc etc....
If this ticker has a 30-35 mill float and a 70ish mill OS, it might just do it on FDA news... and we're laughing!